Literature DB >> 17673012

[Systematic review of anti-tuberculosis drug induced adverse reactions in China].

Yin-yin Xia1, Si-yan Zhan.   

Abstract

OBJECTIVE: To study the incidences of adverse reactions induced by anti-tuberculosis drugs in China.
METHODS: Articles about adverse drug reactions (ADR) induced by anti-tuberculosis drugs published in 1996 - 2005 in China were searched. The incidences, possible risk factors, and prognoses of these ADR were analyzed.
RESULTS: According to our searching strategy and including criteria, 117 studies were included. The overall incidence of anti-tuberculosis drug induced ADR of these studies was 12.62%, and the overall incidence of hepatic injury was 11.9%, which was the highest among all kinds of ADR induced by anti-tuberculosis therapy. For different types of study, different diagnostic standards of hepatic injury, and different study institutions, the reported incidences of hepatic injury varied. Retrospective cohort studies showed that HBV(+) tuberculosis patients had a significantly higher risk of hepatic injury than HBV(-) patients. The prognosis of hepatic injury was good; 85.84% patients were cured of hepatic injury according to the articles which reported outcomes. The whole study was finished by 2006.
CONCLUSIONS: The incidence of adverse reactions induced by anti-tuberculosis drugs is high in China. Prevention and treatment of ADR are very important for improving the adherence of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673012

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  10 in total

1.  CYP2S1 rs338599 polymorphism confers reduced risk to anti-tuberculosis drug-induced liver injury and may be a novel marker for its risk prediction.

Authors:  Liyuan Wang; Hui Wang; Ying Qi
Journal:  J Clin Lab Anal       Date:  2022-05-09       Impact factor: 3.124

2.  Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China.

Authors:  Na Xu; Jing Xiang Yang; Jian Yang
Journal:  Eur J Hosp Pharm       Date:  2020-09-28

3.  Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru.

Authors:  Kocfa Chung-Delgado; Alejandro Revilla-Montag; Sonia Guillen-Bravo; Eduardo Velez-Segovia; Andrea Soria-Montoya; Alexandra Nuñez-Garbin; Wilmer Silva-Caso; Antonio Bernabe-Ortiz
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

4.  Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study.

Authors:  Jing Wang; Ru Chen; Shaowen Tang; Xiaozhen Lv; Shanshan Wu; Yuan Zhang; Yinyin Xia; Pei Gao; Dehua Tu; Dafang Chen; Siyan Zhan
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

5.  Adverse Events in Treating Smear-Positive Tuberculosis Patients in China.

Authors:  Tao Zhang; Jian Du; Xiaoyan Yin; Fuzhong Xue; Yanxun Liu; Runzi Li; Cheng Luo; Liang Li; Xiujun Li
Journal:  Int J Environ Res Public Health       Date:  2015-12-29       Impact factor: 3.390

6.  Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study.

Authors:  Ali Nasir Siddiqui; Khalid Umer Khayyam; Manju Sharma
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

7.  APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study.

Authors:  Junke Qiu; Caihong Wang; Xiaohong Pan; Lei Pan; Xiaoqing Huang; Jiekun Xu; Xiaobo Ji; Minjie Mao
Journal:  BMC Infect Dis       Date:  2019-02-04       Impact factor: 3.090

8.  Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

Authors:  Yin Yin Xia; Dai Yu Hu; Fei Ying Liu; Xiao Meng Wang; Yan Li Yuan; De Hua Tu; Yi Xin Chen; Lin Zhou; Li Zhen Zhu; Wei Wei Gao; Hong Yuan Wang; Da Fang Chen; Li Yang; Ping Ping He; Xiao Ting Li; Ying Jian He; Feng Sun; Si Yan Zhan
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

9.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

10.  Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study.

Authors:  Weiguo Xu; Wei Lu; Yang Zhou; Limei Zhu; Hongbing Shen; Jianming Wang
Journal:  BMC Health Serv Res       Date:  2009-09-18       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.